TetraLogic Pharmaceuticals Competitors

TetraLogic Pharmaceuticals (OTCMKTS:TLOG) and Amarantus BioScience (OTCMKTS:AMBS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for TetraLogic Pharmaceuticals and Amarantus BioScience, as provided by MarketBeat.

Volatility and Risk

TetraLogic Pharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Amarantus BioScience has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

Insider and Institutional Ownership

0.0% of Amarantus BioScience shares are held by institutional investors. 15.4% of TetraLogic Pharmaceuticals shares are held by insiders. Comparatively, 10.3% of Amarantus BioScience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares TetraLogic Pharmaceuticals and Amarantus BioScience's top-line revenue, earnings per share and valuation.

Profitability

This table compares TetraLogic Pharmaceuticals and Amarantus BioScience's net margins, return on equity and return on assets.

Summary

TetraLogic Pharmaceuticals beats Amarantus BioScience on 2 of the 3 factors compared between the two stocks.

TetraLogic Pharmaceuticals (OTCMKTS:TLOG) and Akorn (OTCMKTS:AKRXQ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.

Profitability

This table compares TetraLogic Pharmaceuticals and Akorn's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and target prices for TetraLogic Pharmaceuticals and Akorn, as provided by MarketBeat.

Risk and Volatility

TetraLogic Pharmaceuticals has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Akorn has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Valuation and Earnings

This table compares TetraLogic Pharmaceuticals and Akorn's top-line revenue, earnings per share (EPS) and valuation.

TetraLogic Pharmaceuticals has higher earnings, but lower revenue than Akorn.

Institutional and Insider Ownership

0.1% of Akorn shares are held by institutional investors. 15.4% of TetraLogic Pharmaceuticals shares are held by company insiders. Comparatively, 3.9% of Akorn shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

TetraLogic Pharmaceuticals beats Akorn on 5 of the 7 factors compared between the two stocks.

Immune Pharmaceuticals (OTCMKTS:IMNPQ) and TetraLogic Pharmaceuticals (OTCMKTS:TLOG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Immune Pharmaceuticals and TetraLogic Pharmaceuticals' net margins, return on equity and return on assets.

Risk and Volatility

Immune Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, TetraLogic Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Earnings and Valuation

This table compares Immune Pharmaceuticals and TetraLogic Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a breakdown of recent recommendations for Immune Pharmaceuticals and TetraLogic Pharmaceuticals, as reported by MarketBeat.

Summary

TetraLogic Pharmaceuticals beats Immune Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

TetraLogic Pharmaceuticals (OTCMKTS:TLOG) and VG Life Sciences (OTCMKTS:VGLS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Profitability

This table compares TetraLogic Pharmaceuticals and VG Life Sciences' net margins, return on equity and return on assets.

Risk and Volatility

TetraLogic Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, VG Life Sciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for TetraLogic Pharmaceuticals and VG Life Sciences, as provided by MarketBeat.

Valuation and Earnings

This table compares TetraLogic Pharmaceuticals and VG Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Summary

VG Life Sciences beats TetraLogic Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Innovus Pharmaceuticals (OTCMKTS:INNVD) and TetraLogic Pharmaceuticals (OTCMKTS:TLOG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are held by institutional investors. 16.4% of Innovus Pharmaceuticals shares are held by insiders. Comparatively, 15.4% of TetraLogic Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Innovus Pharmaceuticals and TetraLogic Pharmaceuticals, as provided by MarketBeat.com.

Profitability

This table compares Innovus Pharmaceuticals and TetraLogic Pharmaceuticals' net margins, return on equity and return on assets.

Risk and Volatility

Innovus Pharmaceuticals has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500. Comparatively, TetraLogic Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.

Earnings & Valuation

This table compares Innovus Pharmaceuticals and TetraLogic Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

TetraLogic Pharmaceuticals has lower revenue, but higher earnings than Innovus Pharmaceuticals.

Summary

Innovus Pharmaceuticals beats TetraLogic Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

TetraLogic Pharmaceuticals (OTCMKTS:TLOG) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for TetraLogic Pharmaceuticals and RespireRx Pharmaceuticals, as provided by MarketBeat.com.

Risk & Volatility

TetraLogic Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, RespireRx Pharmaceuticals has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Valuation & Earnings

This table compares TetraLogic Pharmaceuticals and RespireRx Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares TetraLogic Pharmaceuticals and RespireRx Pharmaceuticals' net margins, return on equity and return on assets.

Summary

TetraLogic Pharmaceuticals beats RespireRx Pharmaceuticals on 2 of the 2 factors compared between the two stocks.